Sieluk, Jan http://orcid.org/0000-0002-1833-0273
Slejko, Julia F.
Silverman, Henry
Perfetto, Eleanor
Mullins, C. Daniel
Funding for this research was provided by:
Alpha-1 Foundation (503556)
Article History
Received: 13 December 2019
Accepted: 24 August 2020
First Online: 23 September 2020
Ethics approval and consent to participate
: Institutional Review Board (IRB) approval was obtained from the IRB of the University of Maryland, Baltimore, on July 27, 2016 (HP-00068329).
: Not applicable.
: Jan Sieluk: Research funding from Bayer HealthCare (recipient: University of Maryland, Baltimore), research funding from AlphaNet (recipient: University of Maryland, Baltimore), research funding from Alpha-1 Foundation (recipient: University of Maryland, Baltimore), research funding from American Association of Colleges of Pharmacy (recipient: University of Maryland, Baltimore);Julia F. Slejko: JFS has received funding for research unrelated to the study from Novartis Pharmaceuticals Corporation, Takeda pharmaceuticals, PhRMA and PhRMA Foundation as well as teaching honorarium from Pfizer, Inc., unrelated to study.Eleanor Perfetto: Dr. Perfetto is employed by the National Health Council which receives membership duesand sponsorship support from a variety of organizations. To see the membership and sponsorship organizations, please seeExternalRef removed. Dr. Perfetto has also received grant and contract support from the FDA, Excerpta Medica, and Pfizer Inc.C. Daniel Mullins: Research funding from AlphaNet, Alpha-1 Foundation, Amgen, Bayer, Merck, Novartis, Pfizer (recipient: University of Maryland, Baltimore), consulting income from Amgen, Bayer, Janssen/Johnson & Johnson, MundiPharma, Novartis, Pfizer, Regeneron/Sanofi-Aventis. Robert A. Sandhaus: Medical Director of AlphaNet; medical advisor to Grifols, CSL Behring, Shire, Octapharma, Inhibrx, AstraZeneca; grants from NIH, CSL Behring, Grifols, Matrx.